0731 GMT - Medacta should continue to book above-market growth rates but market expectations currently underestimate growth normalization and the investment required to sustain expansion, Deutsche Bank says in a research note. "While Medacta's competitive advantages remain intact, sustaining its historical growth rates will become increasingly challenging as the business scales," Deutsche Bank says. The bank's 2028 organic sales, adjusted Ebitda and EPS estimates lie 3%, 6% and 9% below consensus, respectively. Deutsche Bank initiates the Swiss orthopedics company's stock at hold, with a target of 121 francs. Shares trade 1.9% lower at 113.20 francs.